Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + FOLFIRI/FOLFOX + thalidomide in first-line treatment of RAS/BRAF wild-type stage IV left colorectal cancer
ChiCTR2300070448Phase 2Not yet recruiting
- Sponsor
- The Third Affiliated Hospital of Chongqing Medical University
- Start
- Jan 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab and thalidomide in colorectal cancer (CRC), sponsored by The Third Affiliated Hospital of Chongqing Medical University. Primary endpoint: Objective response rate (ORR). Planned start Jan 2023; status: not yet recruiting.
02
Drugs
cetuximabthalidomide
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2300070448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070448.